Atea Pharmaceuticals Net Worth
Atea Pharmaceuticals Net Worth Breakdown | AVIR |
Atea Pharmaceuticals Net Worth Analysis
Atea Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Atea Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Atea Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Atea Pharmaceuticals' net worth analysis. One common approach is to calculate Atea Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Atea Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Atea Pharmaceuticals' net worth. This approach calculates the present value of Atea Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Atea Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Atea Pharmaceuticals' net worth. This involves comparing Atea Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Atea Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Atea Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Atea Pharmaceuticals' net worth research are outlined below:
| Net Loss for the year was (168.38 M) with loss before overhead, payroll, taxes, and interest of (83.37 M). | |
| Atea Pharmaceuticals currently holds about 684.48 M in cash with (135.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Atea Pharmaceuticals Receives Outperform Rating from William Blair |
Atea Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Atea Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Atea Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Atea Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Atea Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atea Pharmaceuticals backward and forwards among themselves. Atea Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Atea Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Almitas Capital Llc | 2024-12-31 | 752 K | |
| Northern Trust Corp | 2024-12-31 | 704.9 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 659.5 K | |
| Federated Hermes Inc | 2024-12-31 | 582.9 K | |
| Newtyn Management Llc | 2024-12-31 | 580 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 567 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 493.6 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 409.3 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 390.9 K | |
| Blackrock Inc | 2024-12-31 | 9.1 M | |
| Bml Capital Management Llc | 2024-12-31 | 7.6 M |
Follow Atea Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 255.72 M.Market Cap |
|
Project Atea Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.34) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.36) | (0.34) | |
| Return On Equity | (0.38) | (0.36) |
When accessing Atea Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Atea Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Atea Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Atea Pharmaceuticals' management efficiency
Atea Pharmaceuticals has return on total asset (ROA) of (0.156) % which means that it has lost $0.156 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3388) %, meaning that it created substantial loss on money invested by shareholders. Atea Pharmaceuticals' management efficiency ratios could be used to measure how well Atea Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/10/2025, Return On Tangible Assets is likely to grow to -0.34. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Atea Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 03/10/2025, Other Current Assets is likely to grow to about 10.3 M, while Non Current Assets Total are likely to drop slightly above 2.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.21 | 3.82 | |
| Tangible Book Value Per Share | 5.21 | 3.82 | |
| Enterprise Value Over EBITDA | (1.14) | (1.19) | |
| Price Book Value Ratio | 0.64 | 0.68 | |
| Enterprise Value Multiple | (1.14) | (1.19) | |
| Price Fair Value | 0.64 | 0.68 | |
| Enterprise Value | 219.2 M | 208.3 M |
The operational strategies employed by Atea Pharmaceuticals management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 58.974 | Revenue | Quarterly Revenue Growth 2.952 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atea Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atea Pharmaceuticals Corporate Filings
8K | 6th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 4th of March 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 4th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Atea Pharmaceuticals Earnings per Share Projection vs Actual
Atea Pharmaceuticals Corporate Management
| CPA CPA | Exec Officer | Profile | |
| XiaoJian Zhou | Executive Development | Profile | |
| Jayanthi Wolf | Executive Affairs | Profile | |
| Wayne CPA | Executive Officer | Profile | |
| Ariyapadi Krishnaraj | Vice Marketing | Profile | |
| JeanPierre Sommadossi | Chairman, Founder | Profile | |
| John Vavricka | Chief Officer | Profile |
Already Invested in Atea Pharmaceuticals?
The danger of trading Atea Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Atea Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Atea Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Atea Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.